What is HC Wainwright’s Forecast for Clene FY2026 Earnings?

by · The Markets Daily

Clene Inc. (NASDAQ:CLNN – Free Report) – Stock analysts at HC Wainwright raised their FY2026 EPS estimates for shares of Clene in a research note issued to investors on Wednesday, November 4th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($1.07) per share for the year, up from their prior estimate of ($1.69). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Clene’s current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Clene’s Q4 2026 earnings at ($0.55) EPS, FY2027 earnings at ($0.92) EPS and FY2028 earnings at ($0.60) EPS.

Separately, Weiss Ratings lowered Clene from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, October 27th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Clene has a consensus rating of “Moderate Buy” and a consensus target price of $34.00.

Get Our Latest Stock Report on Clene

Clene Trading Down 3.2%

Shares of Clene stock opened at $3.97 on Friday. The business has a 50-day moving average price of $3.90 and a two-hundred day moving average price of $5.14. Clene has a 1-year low of $3.02 and a 1-year high of $11.23. The company has a market cap of $51.59 million, a P/E ratio of -1.53 and a beta of 1.04.

Clene (NASDAQ:CLNN – Get Free Report) last announced its earnings results on Wednesday, November 4th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.50. The firm had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.07 million.

Clene Company Profile

(Get Free Report)

Clene Inc is a clinical-stage biopharmaceutical company developing nanotherapeutic treatments for neurodegenerative diseases. The company’s lead product candidate, CNM-Au8, is an investigational oral suspension containing catalytically active gold nanocrystals designed to support cellular energy production and reduce oxidative stress, with the goal of protecting and improving the function of nerve cells.

Clene has studied CNM-Au8 in conditions including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), and has also investigated its potential applications in other neurodegenerative disorders.

Featured Stories